<DOC>
	<DOCNO>NCT02503683</DOCNO>
	<brief_summary>The purpose study evaluate Safety , Tolerability , Pharmacokinetics Pharmacodynamics Subcutaneously Administered ALN-AAT Healthy Adult Subjects Patients ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease .</brief_summary>
	<brief_title>A Study Investigational Drug , ALN-AAT , Healthy Adult Subjects Patients With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
	<mesh_term>Alpha 1-Antitrypsin</mesh_term>
	<mesh_term>Protein C Inhibitor</mesh_term>
	<criteria>Adequate complete blood count , liver renal function . 12lead electrocardiogram ( ECG ) within normal limit Female subject must nonchildbearing potential ; e.g . postmenopausal premenopausal surgical sterilization Male subject agree use appropriate contraception Willing provide write informed consent willing comply study requirement Nonsmokers least 5 year screen Any uncontrolled serious disease , medical surgical condition , may interfere participation clinical study and/or put subject significant risk Received investigational agent within 90 day first dose study drug followup another clinical study Active serious mental illness psychiatric disorder require current pharmacological intervention History evidence alcohol drug abuse within 12 month screen . History intolerance SC injection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>RNAi therapeutic</keyword>
	<keyword>AAT</keyword>
	<keyword>Alpha-1 Antitrypsin Deficiency</keyword>
</DOC>